Active substance
Xylometazoline

Indications
Acute respiratory diseases with symptoms of rhinitis (runny nose); Acute allergic rhinitis; Hay fever; Sinusitis; Eustachite; Otitis media (as part of combination therapy to reduce swelling of the nasopharyngeal mucosa); Preparing the patient for diagnostic manipulations in the nasal passages.

Contraindications
Hypersensitivity to xylometazoline or any of the excipients of the drug; Arterial hypertension; Tachycardia; Severe atherosclerosis; Glaucoma; Hyperthyroidism; Atrophic rhinitis; Inflammatory diseases of the skin or mucous membrane of the nasal vestibule; Surgical interventions on the meninges (history); Condition after transsphenoidal hypophysectomy; Pregnancy; Use of monoamine oxidase inhibitors (MAO) (including 14 days after their discontinuation); Use of tricyclic or tetracyclic antidepressants; Children under 2 years of age (for 0.05% solution); Children up to 6 years of age (for 0.1% solution).

Carefully:
  Diabetes; Severe cardiovascular diseases (including coronary heart disease, angina pectoris); Prostatic hyperplasia; Pheochromocytoma; Porphyria; Breastfeeding period; Hypersensitivity to adrenergic drugs, accompanied by insomnia, dizziness, arrhythmia, tremor, increased blood pressure; Patients with long QT syndrome.
Side effects
From the immune system: hypersensitivity reaction (angioedema, rash, itching). From the nervous system: headache. Mental disorders: insomnia, depression (with long-term use in high doses). On the part of the organ of vision: impaired clarity of visual perception. From the heart: palpitations, tachycardia, arrhythmia. From the side of blood vessels: increased blood pressure. From the respiratory system, chest organs and mediastinum: irritation and/or dryness of the nasal mucosa, burning, tingling, sneezing, hypersecretion of the nasopharyngeal mucosa; after using the drug, increased swelling of the nasal mucosa (reactive hyperemia), nosebleeds may be observed. Gastrointestinal disorders: nausea, vomiting. General disorders and reactions at the injection site: burning at the application site.